IL155173A0 - Prophylactic and therapeutic agent for diabetic complications - Google Patents

Prophylactic and therapeutic agent for diabetic complications

Info

Publication number
IL155173A0
IL155173A0 IL15517301A IL15517301A IL155173A0 IL 155173 A0 IL155173 A0 IL 155173A0 IL 15517301 A IL15517301 A IL 15517301A IL 15517301 A IL15517301 A IL 15517301A IL 155173 A0 IL155173 A0 IL 155173A0
Authority
IL
Israel
Prior art keywords
diabetic
diabetic complications
prophylactic
therapeutic agent
complications
Prior art date
Application number
IL15517301A
Other languages
English (en)
Original Assignee
Nissan Chemical Ind Ltd
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd, Kowa Co filed Critical Nissan Chemical Ind Ltd
Publication of IL155173A0 publication Critical patent/IL155173A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/191Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
IL15517301A 2000-10-12 2001-10-11 Prophylactic and therapeutic agent for diabetic complications IL155173A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000311960 2000-10-12
PCT/JP2001/008921 WO2002030425A1 (fr) 2000-10-12 2001-10-11 Medicaments pour la prevention ou le traitement de complications du diabete

Publications (1)

Publication Number Publication Date
IL155173A0 true IL155173A0 (en) 2003-10-31

Family

ID=18791637

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15517301A IL155173A0 (en) 2000-10-12 2001-10-11 Prophylactic and therapeutic agent for diabetic complications

Country Status (21)

Country Link
US (1) US20040087597A1 (fr)
EP (1) EP1325745B1 (fr)
JP (1) JPWO2002030425A1 (fr)
KR (1) KR100830018B1 (fr)
CN (1) CN1230173C (fr)
AT (1) ATE401886T1 (fr)
AU (2) AU2001294221B2 (fr)
CA (1) CA2424060A1 (fr)
CZ (1) CZ2003934A3 (fr)
DE (1) DE60135000D1 (fr)
HK (1) HK1060311A1 (fr)
HU (1) HUP0303353A3 (fr)
IL (1) IL155173A0 (fr)
MX (1) MXPA03003204A (fr)
NO (1) NO20031678L (fr)
NZ (1) NZ525150A (fr)
PL (1) PL361097A1 (fr)
RU (1) RU2003113328A (fr)
SK (1) SK4112003A3 (fr)
WO (1) WO2002030425A1 (fr)
ZA (1) ZA200302507B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4235000B2 (ja) * 2001-04-19 2009-03-04 興和株式会社 糸球体疾患治療剤
JP4719572B2 (ja) * 2003-04-17 2011-07-06 興和株式会社 Lklf/klf2遺伝子発現促進剤
CA2524175C (fr) * 2003-04-28 2016-06-14 Sankyo Company Limited Composition activant l'aptitude a consommer du sucre
JP2005232151A (ja) * 2003-04-28 2005-09-02 Iichiro Shimomura 糖取り込み能増強剤
US9345671B2 (en) 2003-04-28 2016-05-24 Daiichi Sankyo Company, Limited Adiponectin production enhancer
ZA200509286B (en) * 2003-05-23 2007-01-31 Kowa Co Carboxylic compound and medicine comprising the same
WO2006064825A1 (fr) * 2004-12-14 2006-06-22 Santen Pharmaceutical Co., Ltd. Agent therapeutique pour la secheresse oculaire
EP1785133A1 (fr) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique
JPWO2012046772A1 (ja) * 2010-10-06 2014-02-24 国立大学法人 東京大学 リンパ浮腫予防治療剤

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (fr) * 1974-06-07 1981-03-18
US4346772A (en) * 1978-01-03 1982-08-31 Clifft Dale L Power assisting device for a manually operating vehicle
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4588715A (en) * 1984-06-04 1986-05-13 Sandoz, Inc. Heptenoic acid derivatives
US4613610A (en) * 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4804679A (en) * 1984-07-24 1989-02-14 Sandoz Pharm. Corp. Erythro-(E)-7-(3'-C1-3alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl)-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US5001255A (en) * 1984-12-04 1991-03-19 Sandoz Pharm. Corp. Idene analogs of mevalonolactone and derivatives thereof
US4851427A (en) * 1985-10-25 1989-07-25 Sandoz Pharm. Corp. Pyrrole analogs of mevalonolactone, derivatives thereof and pharmaceutical use
US4927851A (en) * 1986-01-07 1990-05-22 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4829081A (en) * 1986-01-07 1989-05-09 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4751235A (en) * 1986-12-23 1988-06-14 Sandoz Pharm. Corp. Anti-atherosclerotic indolizine derivatives
US4939159A (en) * 1986-09-10 1990-07-03 Sandoz Pharm. Corp. Azaindole derivatives useful as cholesterol biosynthesis inhibitors
JP2569746B2 (ja) * 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
EP0308736A3 (fr) * 1987-09-12 1990-02-14 Nissan Chemical Industries Ltd. Mévalonolactones du type pyrimidine
US4868185A (en) * 1987-12-10 1989-09-19 Warner-Lambert Company 6-[[Substituted)pyrimidinyl)ethyl]- and ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
PT91878B (pt) * 1988-10-03 1995-05-31 Glaxo Group Ltd Processo para a preparacao de derivados do imidazole com propriedades hipocolesterolemicas e hipolipidemicas
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
CA2052014A1 (fr) * 1990-10-19 1992-04-20 Henry Y. Pan Methode de prevention des complications du diabete faisant appel a un hypocholesterolemiant seul ou en association avec un inhibiteur de l'enzyme de conversion de l'angiotensine
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
CZ299881B6 (cs) * 1998-07-23 2008-12-17 Nissan Chemical Industries, Ltd. Nitrilová sloucenina a zpusob výroby chinolinového derivátu
GB0001662D0 (en) * 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
EP1161236A1 (fr) * 1999-03-08 2001-12-12 Merck & Co., Inc. Acide ouvert en dihydroxy et sels d'inhibiteurs de la hmg-co-a reductase
JP2004501066A (ja) * 2000-01-28 2004-01-15 ブリストル−マイヤーズ スクイブ カンパニー 脂肪酸結合タンパク質のテトラヒドロピリミドンインヒビターおよび方法
US8186012B2 (en) * 2004-06-03 2012-05-29 The Wooster Brush Company Pole grip with storage compartment

Also Published As

Publication number Publication date
WO2002030425A1 (fr) 2002-04-18
CZ2003934A3 (cs) 2003-11-12
EP1325745A4 (fr) 2005-07-13
HUP0303353A3 (en) 2004-10-28
PL361097A1 (en) 2004-09-20
EP1325745A1 (fr) 2003-07-09
CA2424060A1 (fr) 2003-03-31
AU9422101A (en) 2002-04-22
DE60135000D1 (de) 2008-09-04
JPWO2002030425A1 (ja) 2004-02-19
AU2001294221B2 (en) 2005-09-29
NO20031678D0 (no) 2003-04-11
NZ525150A (en) 2004-10-29
MXPA03003204A (es) 2004-12-03
ZA200302507B (en) 2004-03-31
RU2003113328A (ru) 2004-09-10
SK4112003A3 (en) 2004-01-08
KR100830018B1 (ko) 2008-05-15
HUP0303353A2 (hu) 2004-01-28
ATE401886T1 (de) 2008-08-15
NO20031678L (no) 2003-04-11
US20040087597A1 (en) 2004-05-06
HK1060311A1 (en) 2004-08-06
CN1230173C (zh) 2005-12-07
KR20030060905A (ko) 2003-07-16
CN1469745A (zh) 2004-01-21
EP1325745B1 (fr) 2008-07-23

Similar Documents

Publication Publication Date Title
IL155071A (en) History of glucopyranosyloxybenzylbenzene and their use and pharmaceutical preparations containing them
AU2134402A (en) Antiviral agents
GB0031312D0 (en) Macrolides
MXPA05001581A (es) Algunas imidazopiridinas novedosas y su uso.
HU229581B1 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
LU91854I2 (fr) Eribulin et ses dérivés pharmaceutiquement acceptables (HALAVEN®)
EP1256588A4 (fr) Nouveaux derives de pyrazine ou leurs sels, compositions pharmaceutiques contenant ces derives ou leurs sels et intermediaires utilises dans leur preparation
AR098997A2 (es) Unidad de dosificación que comprende un análogo de prostaglandina para el tratamiento de la constipación
IL155173A0 (en) Prophylactic and therapeutic agent for diabetic complications
WO2002094796A3 (fr) Derives de la benzo[g]quinoxaline composes efficaces contre les maladies infectieuses
NO20060277L (no) Anvendelse av bisyklo [2.2.1] heptanderivater til fremstilling av nevrobeskyttende farmasoytiske sammensetninger
ID27509A (id) Turunan piridin tersubstitusi-2,3 proses pembuatannya, komposisi farmasi yang mengandung senyawa tersebut, dan senyawa-antaranya
EP1326596A4 (fr) Preparations pharmaceutiques contenant un derive lignane du dibenzocyclooctane et permettant de prevenir et de traiter les maladies neurodegeneratives
DE60013560D1 (de) Malto-oligosaccharid-derivate und ihre anwendungen
EP1325748A4 (fr) Medicaments preventifs ou therapeutiques contre le cancer ayant comme principe actif des composes de cyanidine
EP1306087A4 (fr) Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
EP1179342A4 (fr) Compositions medicinales a liberation immediate pour administration orale
BR0104359A (pt) Decursinol ou seus derivados a partir de agenteanalgésico
WO2002041891A3 (fr) Traitement de l'infection par le vih
EP1362593A4 (fr) Composition pharmaceutique pour traiter la neuropathie diabetique
EP1291349A4 (fr) Derives de malto-oligosaccharide et utilisation correspondante
TW200633714A (en) Drugs for the treatment and/or prophylaxis of gastroparesis symptom
AU8008401A (en) Amphotericin b structured emulsion
IL160603A0 (en) C2-disubstituted indan-1-ol systems and their derivatives, processes for their preparation and their use as pharmaceuticals
GEP20053513B (en) 2-Aminocarbonyl-9H-Purine Derivatives